Orchard Capital Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $195K | Hold |
53,510
| – | – | 0.22% | 36 |
|
|
2025
Q1 | $103K | Sell |
53,510
-7,200
| -12% | -$13.8K | 0.07% | 38 |
|
|
2024
Q4 | $115K | Sell |
60,710
-24,006
| -28% | -$45.6K | 0.05% | 55 |
|
|
2024
Q3 | $112K | Sell |
84,716
-2,110
| -2% | -$2.79K | 0.04% | 55 |
|
|
2024
Q2 | $88.6K | Sell |
86,826
-21,634
| -20% | -$22.1K | 0.03% | 42 |
|
|
2024
Q1 | $198K | Buy |
108,460
+21,634
| +25% | +$39.6K | 0.06% | 47 |
|
|
2023
Q4 | $108K | Buy |
86,826
+20,000
| +30% | +$24.8K | 0.03% | 44 |
|
|
2023
Q3 | $76.2K | Hold |
66,826
| – | – | 0.03% | 42 |
|
|
2023
Q2 | $61.1K | Hold |
66,826
| – | – | 0.02% | 46 |
|
|
2023
Q1 | $37.4K | Hold |
66,826
| – | – | 0.01% | 48 |
|
|
2022
Q4 | $38.6K | Sell |
66,826
-185,000
| -73% | -$107K | 0.01% | 50 |
|
|
2022
Q3 | $80K | Hold |
251,826
| – | – | 0.03% | 46 |
|
|
2022
Q2 | $89K | Sell |
251,826
-1,510,905
| -86% | -$534K | 0.03% | 47 |
|
|
2022
Q1 | $1.27M | Buy |
1,762,731
+169,200
| +11% | +$121K | 0.36% | 36 |
|
|
2021
Q4 | $3.6M | Hold |
1,593,531
| – | – | 1.06% | 29 |
|
|
2021
Q3 | $4.59M | Hold |
1,593,531
| – | – | 1.38% | 29 |
|
|
2021
Q2 | $6.04M | Buy |
1,593,531
+53,277
| +3% | +$202K | 1.74% | 27 |
|
|
2021
Q1 | $5.21M | Buy |
1,540,254
+683,116
| +80% | +$2.31M | 1.64% | 29 |
|
|
2020
Q4 | $2.4M | Buy |
+857,138
| New | +$2.4M | 1.02% | 32 |
|